Takeuchi, Masashi
Kawakubo, Hirofumi
Shimada, Ayako
Matsuda, Satoru
Nakahara, Tadaki
Mayanagi, Shuhei
Irino, Tomoyuki
Fukuda, Kazumasa
Nakamura, Rieko
Wada, Norihito
Takeuchi, Hiroya
Kitagawa, Yuko
Article History
Received: 12 September 2019
Accepted: 30 October 2019
First Online: 14 November 2019
Compliance with ethical standards
:
: Yuko Kitagawa received Grant support from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd., Yakult Honsha Co. Ltd., Daiichi Sankyo Company, Limited, Merck Serono Co., Ltd., Asahi Kasei Co., Ltd., EA Pharma Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Factory Inc., Shionogi & Co., Ltd., Kaken Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., Astellas Pharma Inc., Medicon Inc., Dainippon Sumitomo Pharma Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Kyouwa Hakkou Kirin Co., Ltd., Pfizer Japan Inc., Ono Pharmaceutical Co., Ltd., Nihon Pharmaceutical Co., Ltd., Japan Blood Products Organization, Medtronic Japan Co., Ltd., Sanofi K.K., Grants from Eisai Co., Ltd., Tsumura & Co., KCI Licensing, Inc., Abbott Japan Co., Ltd., and Fujifilm Toyama Chemical Co., Ltd.
: All procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent or substitute for it was obtained from all patients for being included in the study.
Free to read: This content has been made available to all.